Source: Future Medicinal Chemistry. Unidade: IFSC
Subjects: FÁRMACOS, PLANEJAMENTO DE FÁRMACOS, DOENÇAS PARASITÁRIAS, DOENÇA DE CHAGAS, TRYPANOSOMA CRUZI
ABNT
DOBRACHINSKI, Leandro et al. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. Future Medicinal Chemistry, v. 16, n. 17, p. 1791-1799, 2024Tradução . . Disponível em: https://doi.org/10.1080/17568919.2024.2379231. Acesso em: 05 nov. 2024.APA
Dobrachinski, L., Ferreira, L. L. G., Cirino, M. E. de, Siqueira, A. I. A. de, Mafud, A. C., Mascarenhas, Y. P., et al. (2024). The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. Future Medicinal Chemistry, 16( 17), 1791-1799. doi:10.1080/17568919.2024.2379231NLM
Dobrachinski L, Ferreira LLG, Cirino ME de, Siqueira AIA de, Mafud AC, Mascarenhas YP, Andricopulo AD, Moraes J de. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs [Internet]. Future Medicinal Chemistry. 2024 ; 16( 17): 1791-1799.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1080/17568919.2024.2379231Vancouver
Dobrachinski L, Ferreira LLG, Cirino ME de, Siqueira AIA de, Mafud AC, Mascarenhas YP, Andricopulo AD, Moraes J de. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs [Internet]. Future Medicinal Chemistry. 2024 ; 16( 17): 1791-1799.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1080/17568919.2024.2379231